Delta immune ecology of NSCLC in KRAS-mutant cancers
Official title: Project 1: Delta immune Ecology of NSCLC
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11416427 · Data updated 2026-11-12
A study in people with NSCLC (especially KRAS-mutant) will examine how immune cells and tumor interactions change during treatment and how this could guide better therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $367,281 |
| NIH project number | 5U54CA274507-04 |
| Project ID | NIH-11416427 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with non-small cell lung cancer, especially those with KRAS mutations, who are participating in related clinical trials and provide pre- and on-treatment biopsies.
✕Less likely to help
Patients not undergoing the associated clinical trial or lacking KRAS-mutant NSCLC may not directly benefit.
What this research studies
This project will look at how the tumor and immune system interact in non-small cell lung cancer, focusing on KRAS-mutant tumors, during pre-treatment and on-treatment periods. Researchers will analyze biopsies with advanced imaging and computational methods to map the spatial relationships of cells and how they evolve with therapy. They plan to build spatiotemporal biomarkers and use mathematical models to help tailor treatment strategies, including combinations of targeted therapies and immunotherapy. The work leverages clinical trial samples and state-of-the-art analytics to understand why some tumors respond and others resist therapy.
Why it matters
Potential benefit: If successful, patients could benefit from more precise treatment approaches that adapt to how their tumor ecology changes during therapy.
How similar studies have gone: Previous work has shown that spatial tumor-immune interactions can influence response, with groundwork suggesting ecology-guided strategies could improve outcomes.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Anderson, Alexander Robertson Allan — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Anderson, Alexander Robertson Allan
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.